The findings could add momentum for F.D.A. authorization of the pediatric dose, perhaps as early as next week, a long-awaited development that would affect 28 million children.The findings could add momentum for F.D.A. authorization of the pediatric dose, perhaps as early as next week, a long-awaited development that would affect 28 million children.Clinical Trials, Coronavirus (2019-nCoV), Vaccination and Immunization, Children and Childhood, Coronavirus Risks and Safety Concerns, Pfizer Inc, BioNTech SE, Food and Drug AdministrationRead More
